Xuejie Jiang
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 36 publications
Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.
Journal: Experimental hematology & oncology
Published: March 25, 2026
Impact of RUNX1 mutations at distinct sites on the clinical characteristics and prognosis of patients with acute myeloid leukemia.
Journal: BMC cancer
Published: January 02, 2026
ALDH3A2-mediated fatty acid synthesis induces ferroptosis and AML drug resistance.
Journal: iScience
Published: July 25, 2025
The clinical utility of metagenomic next-generation sequencing in the management of fever in patients with hematological disorders.
Journal: Nagoya journal of medical science
Published: June 17, 2025
Clinical efficacy and safety of venetoclax combined with hypomethylating agents in relapsed high-risk acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation.
Journal: Frontiers in medicine
Published: June 03, 2025
High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.
Journal: Leukemia
Published: January 20, 2025
Venetoclax added to CLAG regimen might improve the outcome of patients with relapsed/refractory acute myeloid leukemia.
Journal: Therapeutic advances in hematology
Published: August 12, 2024
Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia-related mutations in first remission.
Journal: British journal of haematology
Published: August 08, 2024
Homoharringtonine may help improve the outcomes of venetoclax and azacitidine in AML1-ETO positive acute myeloid leukemia.
Journal: Journal of cancer research and clinical oncology
Published: May 27, 2024
Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis.
Journal: Cell communication and signaling : CCS
Published: May 01, 2024
Homoharringtonine Added to Venetoclax and Azacitidine Improves Outcome and Mitigates Genetic Impact in Relapsed/Refractory AML: A Multicenter Cohort Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 30, 2024
Last Updated: 09/26/2026